Re: Farmas USA
CEMP ahora MLNT
Con muy poco volumen pero ha llegado a hacer hasta un + 20% o tocado los 14.70 con solo 2M de share float
ahora mismo cotizando a 13.85 y abrio a 11.35.
No esta mal para ser 1er dia de cotizacion en el NASDAQ despues de la fusion. Melinta/CEMP
Cuando era solo CEMP el pasado Jueves cerro su market cap sobre los 180M los otro lo ha aportado la No Cotizada Melinta
Tras la fusion y con el 20% que ha subido hoy ya el Market Cap se ha disparado a + 648 millones /usd pero con solo 2 M de shares float asi que este en pocos dias tendra que cambiar , o hay aqui un error
-- ------
MELINTA PARTNERSHIPS
MENARINI
In March 2017, Melinta licensed rights to delafloxacin (known as Baxdela in the U.S.) to the Menarini Group in 68 countries in Europe, Asia-Pacific, and the Commonwealth of Independent States (CIS) listed below.
In June 2015, Melinta and Malin Plc entered into an agreement for the commercialization and distribution of delafloxacin (known as Baxdela in the U.S.) in certain countries in the Middle East and Africa listed below. Under the terms of their agreement, Melinta gains access to Malin’s global network of biotechnology and pharmaceutical companies, expanding delafloxacin’s commercial potential to include the emerging nations Middle East and Africa
n January 2015, Melinta and Eurofarma Laboratórios, one of the largest pharmaceutical companies in Brazil and present in more than 20 countries in Latin America, entered into an agreement for the development and commercialization of delafloxacin (known as Baxdela in the US) in Brazil. In August 2017, the companies amended the agreement to cover all countries in Latin America. 
n January 2015, Melinta and Eurofarma Laboratórios, one of the largest pharmaceutical companies in Brazil and present in more than 20 countries in Latin America, entered into an agreement for the development and commercialization of delafloxacin (known as Baxdela in the US) in Brazil. In August 2017, the companies amended the agreement to cover all countries in Latin America.
We have licensed solithromycin to Toyama Chemical Co., Ltd., or Toyama, for development and commercialization in Japan while retaining the rights to the rest of the world. Toyama has successfully completed a Phase 1 trial in healthy Japanese volunteers, a Phase 1 trial to measure solithromycin levels in the upper respiratory tract, and a Phase 2 trial in CABP. In December 2016, Toyama initiated Phase 3 trials in patients infected with CABP and other respiratory infections. Toyama and we are sharing the results of our respective development 
